PTU-110 Long-Term Safety of Teduglutide Treatment for Patients with Intestinal Failure Associated with Short Bowel Syndrome: Pooled Data from 4 Clinical Trials

@inproceedings{Gabe2016PTU110LS,
  title={PTU-110 Long-Term Safety of Teduglutide Treatment for Patients with Intestinal Failure Associated with Short Bowel Syndrome: Pooled Data from 4 Clinical Trials},
  author={Simon M Gabe and U F Pape and E Delmaestro and Bailian Li and Nabil N Youssef and Doug Seidner},
  year={2016}
}
Introduction Teduglutide (TED) is indicated for the treatment of adults with intestinal failure associated with short bowel syndrome (SBS-IF) who are dependent on parenteral support (PS). In phase III randomised placebo-controlled trials, TED significantly reduced PS volume requirements and number of PS infusion days per week in patients (pts) with SBS-IF. Here, we present combined safety data from TED-treated pts in these trials and their respective open-label extension studies. Methods Safety… CONTINUE READING

Topics from this paper.

Similar Papers